2024 Q2 Form 10-Q Financial Statement
#000115903624000037 Filed on May 07, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $231.4M | $195.9M |
| YoY Change | 4.67% | 20.81% |
| Cost Of Revenue | $39.61M | $28.33M |
| YoY Change | -20.9% | -19.45% |
| Gross Profit | $191.7M | $167.6M |
| YoY Change | 12.15% | 31.96% |
| Gross Profit Margin | 82.88% | 85.54% |
| Selling, General & Admin | $35.71M | $35.13M |
| YoY Change | -8.31% | -5.95% |
| % of Gross Profit | 18.62% | 20.97% |
| Research & Development | $21.04M | $19.11M |
| YoY Change | 6.65% | 6.3% |
| % of Gross Profit | 10.97% | 11.41% |
| Depreciation & Amortization | $2.600M | $2.400M |
| YoY Change | -7.14% | -7.69% |
| % of Gross Profit | 1.36% | 1.43% |
| Operating Expenses | $56.75M | $54.25M |
| YoY Change | -3.28% | -1.97% |
| Operating Profit | $117.2M | $95.54M |
| YoY Change | 24.11% | 77.58% |
| Interest Expense | $508.0K | $4.507M |
| YoY Change | -88.7% | -0.79% |
| % of Operating Profit | 0.43% | 4.72% |
| Other Income/Expense, Net | $5.032M | $4.993M |
| YoY Change | 57.64% | 67.61% |
| Pretax Income | $117.7M | $96.03M |
| YoY Change | 26.39% | 83.83% |
| Income Tax | $24.50M | $19.20M |
| % Of Pretax Income | 20.81% | 19.99% |
| Net Earnings | $93.25M | $76.82M |
| YoY Change | 24.74% | 93.92% |
| Net Earnings / Revenue | 40.3% | 39.22% |
| Basic Earnings Per Share | $0.73 | $0.61 |
| Diluted Earnings Per Share | $0.72 | $0.60 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 127.3M shares | 126.8M shares |
| Diluted Shares Outstanding | 129.2M shares | 128.9M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $529.0M | $463.5M |
| YoY Change | 51.9% | 68.16% |
| Cash & Equivalents | $187.9M | $164.6M |
| Short-Term Investments | $341.2M | $298.8M |
| Other Short-Term Assets | $84.93M | $45.69M |
| YoY Change | 118.42% | 23.46% |
| Inventory | $159.3M | $168.5M |
| Prepaid Expenses | $30.93M | $36.21M |
| Receivables | $210.4M | $185.3M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $987.8M | $873.6M |
| YoY Change | 29.0% | 42.04% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $40.21M | $41.89M |
| YoY Change | 11.54% | 8.67% |
| Goodwill | $416.8M | $416.8M |
| YoY Change | 0.0% | 0.14% |
| Intangibles | $437.4M | $455.1M |
| YoY Change | -14.41% | -13.94% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $52.48M | $17.94M |
| YoY Change | 23.97% | -70.8% |
| Total Long-Term Assets | $981.7M | $967.9M |
| YoY Change | -6.03% | -10.74% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $987.8M | $873.6M |
| Total Long-Term Assets | $981.7M | $967.9M |
| Total Assets | $1.969B | $1.842B |
| YoY Change | 8.78% | 8.36% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $15.43M | $13.33M |
| YoY Change | 52.47% | 53.25% |
| Accrued Expenses | $117.9M | $118.3M |
| YoY Change | 11.86% | 47.93% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $133.4M | $131.6M |
| YoY Change | 14.58% | 43.21% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.503B | $1.501B |
| YoY Change | 0.44% | 0.43% |
| Other Long-Term Liabilities | $30.51M | $31.20M |
| YoY Change | -1.19% | 5.51% |
| Total Long-Term Liabilities | $1.533B | $1.532B |
| YoY Change | 0.4% | 0.53% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $133.4M | $131.6M |
| Total Long-Term Liabilities | $1.533B | $1.532B |
| Total Liabilities | $1.680B | $1.664B |
| YoY Change | 1.24% | 1.84% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $260.6M | $167.4M |
| YoY Change | 85.56% | 154.78% |
| Common Stock | $30.87M | $11.92M |
| YoY Change | 153.07% | 8931.06% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $289.4M | $177.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.969B | $1.842B |
| YoY Change | 8.78% | 8.36% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $93.25M | $76.82M |
| YoY Change | 24.74% | 93.92% |
| Depreciation, Depletion And Amortization | $2.600M | $2.400M |
| YoY Change | -7.14% | -7.69% |
| Cash From Operating Activities | $55.79M | $129.4M |
| YoY Change | -16.53% | 48.83% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $2.582M | $3.545M |
| YoY Change | -259.09% | -68.84% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$39.46M | -$79.14M |
| YoY Change | -173.93% | 62.21% |
| Cash From Investing Activities | -$42.04M | -$82.68M |
| YoY Change | -176.44% | 37.43% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 9.482M | -$489.0K |
| YoY Change | 287.65% | -99.7% |
| NET CHANGE | ||
| Cash From Operating Activities | 55.79M | $129.4M |
| Cash From Investing Activities | -42.04M | -$82.68M |
| Cash From Financing Activities | 9.482M | -$489.0K |
| Net Change In Cash | 23.24M | $46.26M |
| YoY Change | -81.3% | -133.57% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $55.79M | $129.4M |
| Capital Expenditures | $2.582M | $3.545M |
| Free Cash Flow | $53.21M | $125.9M |
| YoY Change | -22.28% | 66.54% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent | |
| CY2024Q1 | us-gaap |
Derivative Liability Current Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent | |
| CY2024Q1 | us-gaap |
Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent | |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
1663719000 | usd |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
1649462000 | usd |
| CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
127186000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
127186000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
127000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
127000 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
11794000 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2409000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1486000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-9278000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
167373000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
90550000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
177808000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
83808000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1841527000 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1733270000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
195879000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
162143000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
28329000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
35170000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17763000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17835000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
19111000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17979000 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
35134000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
37357000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
100337000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
108341000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
95542000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
53802000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
4993000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2979000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
4507000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
4543000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
96028000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
52238000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
19205000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12623000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76823000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39615000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.61 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.29 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.60 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.29 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
126941000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
135027000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
128887000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
137900000 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76823000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39615000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-313000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
924000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
8000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
22000 | usd |
| CY2024Q1 | halo |
Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
|
8615000 | usd |
| CY2023Q1 | halo |
Other Comprehensive Income Loss Cash Flow Hedge Unrealized Holding Gain Loss Before Adjustment After Tax
OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
|
0 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
|
-518000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
|
0 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
84615000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
40561000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76823000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39615000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9874000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7966000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2443000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2622000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17763000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17835000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
1830000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
1835000 | usd |
| CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2365000 | usd |
| CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
917000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
7000 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd |
| CY2024Q1 | halo |
Deferred Rent Payments
DeferredRentPayments
|
-220000 | usd |
| CY2023Q1 | halo |
Deferred Rent Payments
DeferredRentPayments
|
-320000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
-1291000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
-3874000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-38308000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-36189000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
40233000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
7250000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-4795000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-8881000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
18685000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-24006000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
129427000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
86964000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
198763000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
109919000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
119627000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
61134000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3545000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
11377000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-82681000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-60162000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
13483000 | usd |
| CY2024Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
150083000 | usd |
| CY2024Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
489000 | usd |
| CY2023Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1048000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-489000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-164614000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
46257000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-137812000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
118370000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
234695000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
164627000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
96883000 | usd |
| CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1515000 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
390000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1242000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
406000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
| CY2023Q1 | us-gaap |
Stock Issued1
StockIssued1
|
125000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
83808000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9874000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
-489000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
7792000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76823000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
177808000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
169798000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7966000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
-126000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
-1048000 | usd |
| CY2023Q1 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
151301000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
946000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39615000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
65850000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the innovators of ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids with the goal of reducing the treatment burden for patients. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE partners’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc. (“Takeda”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), argenx BVBA (“argenx”), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (“ViiV”), Chugai Pharmaceutical Co., Ltd. (“Chugai”) and Acumen Pharmaceuticals, Inc. (“Acumen”). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from sales of seven commercial products including sales of one commercial product from each of the Takeda, Janssen and argenx collaborations and four commercial products products from the Roche collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (“Teva”) and Otter Pharmaceuticals, LLC (“Otter”). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (“Idorsia”).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing rHuPH20, and XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing our auto-injector technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to our condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries as disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> | |
| CY2024Q1 | halo |
Royalties Received Number Of Products Sold
RoyaltiesReceivedNumberOfProductsSold
|
7 | product |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates | |
| CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | usd |
| CY2024Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | usd |
| CY2024Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.20 | |
| CY2024Q1 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
500000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
|
<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. | |
| CY2024Q1 | us-gaap |
Derivatives Methods Of Accounting Hedging Derivatives
DerivativesMethodsOfAccountingHedgingDerivatives
|
<div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges - Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March 31, 2024, all hedges were determined to be highly effective. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (“AOCI”) within stockholder’s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March 31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.</span></div> | |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
19200000 | usd |
| CY2024Q1 | halo |
Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
|
P90D | |
| CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
|
298983000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
38000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
197000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
298824000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
|
217475000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
201000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
46000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
217630000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
33 | security |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
215500000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
200000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
|
0 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
235059000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
197633000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
63765000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
19997000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
298824000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
217630000 | usd |
| CY2024Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
350674000 | usd |
| CY2023Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
241772000 | usd |
| CY2024Q1 | us-gaap |
Derivative Assets Current
DerivativeAssetsCurrent
|
1300000 | usd |
| CY2024Q1 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
300000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
195879000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
162143000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
|
14000000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
-100000 | usd |
| CY2024Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
185313000 | usd |
| CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
233254000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
|
10589000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
|
956000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4595000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4048000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4600000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4600000 | usd |
| CY2024Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
1200000 | usd |
| CY2024Q1 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2024Q1 | us-gaap |
Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
|
10600000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
|
10589000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
|
956000 | usd |
| CY2024Q1 | halo |
Accounts Receivable And Contract With Customer Asset Before Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent
|
202111000 | usd |
| CY2023Q4 | halo |
Accounts Receivable And Contract With Customer Asset Before Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent
|
240957000 | usd |
| CY2024Q1 | halo |
Accounts Receivable And Contract With Customer Asset Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent
|
6209000 | usd |
| CY2023Q4 | halo |
Accounts Receivable And Contract With Customer Asset Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent
|
6747000 | usd |
| CY2024Q1 | halo |
Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
|
195902000 | usd |
| CY2023Q4 | halo |
Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current
AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent
|
234210000 | usd |
| CY2024Q1 | halo |
Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
78071000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
29112000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
23646000 | usd |
| CY2024Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
43611000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
34025000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
95818000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
69930000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
168541000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
127601000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
36211000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
36850000 | usd |
| CY2024Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
13847000 | usd |
| CY2023Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
12902000 | usd |
| CY2024Q1 | us-gaap |
Other Assets
OtherAssets
|
12951000 | usd |
| CY2023Q4 | us-gaap |
Other Assets
OtherAssets
|
16677000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
63009000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
66429000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
17319000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
17816000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
45690000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
48613000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
63066000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
57769000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
21180000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
19661000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
41886000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
38108000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
36185000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
36836000 | usd |
| CY2023Q4 | halo |
Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
74944000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2400000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2600000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1400000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1400000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
|
10442000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
|
17361000 | usd |
| CY2024Q1 | halo |
Accrued Outsourced Manufacturing Expenses
AccruedOutsourcedManufacturingExpenses
|
27456000 | usd |
| CY2023Q4 | halo |
Accrued Outsourced Manufacturing Expenses
AccruedOutsourcedManufacturingExpenses
|
12361000 | usd |
| CY2024Q1 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
19074000 | usd |
| CY2023Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
963000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
|
39941000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
|
41932000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
|
20839000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
|
33584000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
31763000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
32197000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
149515000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
138398000 | usd |
| CY2024Q1 | halo |
Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
|
31201000 | usd |
| CY2023Q4 | halo |
Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
|
37720000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
118314000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
100678000 | usd |
| CY2024Q1 | halo |
Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
|
600000 | usd |
| CY2023Q1 | halo |
Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
|
700000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2000000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2100000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1800000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1700000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
416821000 | usd |
| CY2024Q1 | us-gaap |
Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
|
0 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
416821000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
538200000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
131784000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
406416000 | usd |
| CY2024Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
48700000 | usd |
| CY2024Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
455116000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
53286000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
71049000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
71049000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
71049000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
71049000 | usd |
| CY2024Q1 | halo |
Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
|
68934000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
406416000 | usd |
| CY2023Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
13500000 | usd |
| CY2023Q1 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
288886 | shares |
| CY2024Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
1525000000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
1525000000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
24121000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
25752000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
1500879000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
1499248000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Fair Value
DebtInstrumentFairValue
|
1416647000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Fair Value
DebtInstrumentFairValue
|
1366348000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9874000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7966000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9874000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7966000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
500000 | shares |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1200000 | shares |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y9M18D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0380 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0428 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0348 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0427 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2021Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
750000000 | usd |
| CY2021Q4 | us-gaap |
Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
|
P3Y | |
| CY2021 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
3900000 | shares |
| CY2021 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
150000000 | usd |
| CY2021 | us-gaap |
Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
|
38.51 | |
| CY2022 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
4500000 | shares |
| CY2022 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
200000000 | usd |
| CY2022 | us-gaap |
Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
|
44.44 | |
| us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
12600000 | shares | |
| us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
500000000 | usd | |
| us-gaap |
Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
|
39.81 | ||
| CY2021Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
750000000 | usd |
| CY2021Q4 | us-gaap |
Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
|
P3Y | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76823000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39615000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
126941000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
135027000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
128887000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
137900000 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.61 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.29 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.60 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.29 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
28200000 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
26200000 | shares |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false |
